J. Wolf

714 total citations
29 papers, 530 citations indexed

About

J. Wolf is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, J. Wolf has authored 29 papers receiving a total of 530 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 13 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in J. Wolf's work include Lung Cancer Treatments and Mutations (18 papers), Lung Cancer Research Studies (5 papers) and Migraine and Headache Studies (4 papers). J. Wolf is often cited by papers focused on Lung Cancer Treatments and Mutations (18 papers), Lung Cancer Research Studies (5 papers) and Migraine and Headache Studies (4 papers). J. Wolf collaborates with scholars based in Germany, United States and Japan. J. Wolf's co-authors include Daniel P. Potaczek, Holger Garn, Fahd Alhamdan, Hani Harb, Bilal Alashkar Alhamwe, Harald Renz, Antonio Ferrante, Verena von Bülow, Susan L. Prescott and Charles S. Hii and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics and Annals of Oncology.

In The Last Decade

J. Wolf

27 papers receiving 517 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J. Wolf Germany 10 248 214 167 71 60 29 530
Xinyang Liao China 13 171 0.7× 161 0.8× 131 0.8× 41 0.6× 19 0.3× 58 545
Ioannis Vamvakaris Greece 10 159 0.6× 168 0.8× 268 1.6× 88 1.2× 19 0.3× 35 530
Corrina M. de Ridder Netherlands 12 203 0.8× 275 1.3× 129 0.8× 25 0.4× 19 0.3× 12 557
Sheng Cheng China 13 162 0.7× 97 0.5× 78 0.5× 62 0.9× 24 0.4× 45 459
Lei‐Ya Fang Taiwan 7 220 0.9× 185 0.9× 133 0.8× 33 0.5× 25 0.4× 7 519
Haojun Yang China 13 199 0.8× 54 0.3× 73 0.4× 20 0.3× 31 0.5× 38 380
Peter M. Gulleman United States 13 171 0.7× 325 1.5× 99 0.6× 170 2.4× 13 0.2× 17 695
Julien Ancel France 12 140 0.6× 135 0.6× 131 0.8× 28 0.4× 13 0.2× 39 356
Jean‐Jacques Cassiman Belgium 16 341 1.4× 253 1.2× 35 0.2× 74 1.0× 51 0.8× 22 680
Herbert Archer United States 8 124 0.5× 81 0.4× 123 0.7× 41 0.6× 11 0.2× 9 411

Countries citing papers authored by J. Wolf

Since Specialization
Citations

This map shows the geographic impact of J. Wolf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Wolf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Wolf more than expected).

Fields of papers citing papers by J. Wolf

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Wolf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Wolf. The network helps show where J. Wolf may publish in the future.

Co-authorship network of co-authors of J. Wolf

This figure shows the co-authorship network connecting the top 25 collaborators of J. Wolf. A scholar is included among the top collaborators of J. Wolf based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Wolf. J. Wolf is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Goto, Keiko, Benjamin Solomon, K. Park, et al.. (2023). LBA4 Randomized phase III study of first-line selpercatinib versus chemotherapy and pembrolizumab in RET fusion-positive NSCLC. Annals of Oncology. 34. S1303–S1303. 4 indexed citations
2.
3.
Danno, Daisuke, Kazumasa Saigoh, J. Wolf, et al.. (2022). Hemiplegic migraine type 2 with new mutation of the ATP1A2 gene in Japanese cases. Neuroscience Research. 180. 83–89. 6 indexed citations
4.
5.
Goto, Kōichi, J. Wolf, Yasir Y. Elamin, et al.. (2021). FP14.05 LIBRETTO-431: Selpercatinib in Treatment-Naïve Patients with RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC).. Journal of Thoracic Oncology. 16(3). S228–S229. 5 indexed citations
6.
Bashir, Sanum, et al.. (2020). Enhancement of CRISPR-Cas9 induced precise gene editing by targeting histone H2A-K15 ubiquitination. BMC Biotechnology. 20(1). 57–57. 11 indexed citations
7.
Koleczko, Sophia & J. Wolf. (2020). Immuncheckpointinhibitoren beim Lungenkarzinom. Der Internist. 61(7). 676–681. 4 indexed citations
8.
Danno, Daisuke, et al.. (2020). Cranial Autonomic Symptoms of Migraine in Japan: Prospective Study of 373 Migraine Patients at a Tertiary Headache Center. Headache The Journal of Head and Face Pain. 60(8). 1592–1600. 19 indexed citations
9.
Abbring, Suzanne, J. Wolf, Mara A. P. Diks, et al.. (2019). Raw Cow’s Milk Reduces Allergic Symptoms in a Murine Model for Food Allergy—A Potential Role for Epigenetic Modifications. Nutrients. 11(8). 1721–1721. 34 indexed citations
10.
Paz-Ares, L., Rafał Dziadziuszko, A. Drilon, et al.. (2019). MA14.02 Entrectinib in Patients with ROS1-Positive NSCLC or NTRK Fusion-Positive Solid Tumors with CNS Metastases. Journal of Thoracic Oncology. 14(10). S305–S305. 5 indexed citations
11.
Demetri, George D., Luis Paz‐Ares, Anna F. Farago, et al.. (2018). Efficacy and safety of entrectinib in patients with NTRK fusion-positive (NTRK-fp) Tumors: Pooled analysis of STARTRK-2, STARTRK-1 and ALKA-372-001. Annals of Oncology. 29. viii713–viii713. 46 indexed citations
12.
Nogová, Lucia, Florian Malchers, Axel M. Hillmer, et al.. (2018). P1.01-72 FIND Trial: A Phase II Study to Evaluate the Efficacy of the FGFR-Inhibitor Erdafitinib in FGFR-Mutated and -Translocated Squamous NSCLC. Journal of Thoracic Oncology. 13(10). S490–S490. 1 indexed citations
13.
Alhamwe, Bilal Alashkar, J. Wolf, Verena von Bülow, et al.. (2018). Histone modifications and their role in epigenetics of atopy and allergic diseases. Allergy Asthma and Clinical Immunology. 14(1). 39–39. 170 indexed citations
14.
Koleczko, Sophia, Matthias Scheffler, Michaela A. Ihle, et al.. (2016). A comprehensive analysis of potentially targetable genetic aberrations and clinical findings in 821 patients with squamous-cell NSCLC – a comparison of NGM and TCGA LUSC data. Annals of Oncology. 27. vi420–vi420. 1 indexed citations
15.
Zalcman, Gérard, Naiyer A. Rizvi, H. Léna, et al.. (2015). Phase 2 Study of Nivolumab (ANTI-PROGRAMMED DEATH-1 [PD-1]) in Patients (PTS) with Advanced, Refractory Squamous (SQ) Non-Small Cell Lung Cancer (NSCLC). Annals of Oncology. 26. i29–i29. 1 indexed citations
16.
Shaw, Alice T., Lucio Crinò, Enriqueta Felip, et al.. (2014). Two Phase III Studies Evaluating Ceritinib in Patients (Pts) with Anaplastic Lymphoma Kinase (Alk)-Rearranged (Alk+) Non-Small Cell Lung Cancer (Nsclc): Ascend-4 and Ascend-5. Annals of Oncology. 25. iv469–iv469. 4 indexed citations
17.
Wolf, J.. (2011). Prinzipien der individualisierten, zielgerichteten Therapie am Beispiel des nicht-kleinzelligen Bronchialkarzinoms. DMW - Deutsche Medizinische Wochenschrift. 136(10). 480–485. 2 indexed citations
18.
Stoelben, Erich, Rudolf M. Huber, R.-P. Müller, & J. Wolf. (2010). Multimodale Therapie des Lungenkarzinoms. Der Internist. 51(11). 1348–1357. 3 indexed citations
19.
Soria, Jean‐Charles, Frances A. Shepherd, Jean‐Yves Douillard, et al.. (2009). Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. Annals of Oncology. 20(10). 1674–1681. 139 indexed citations
20.
Diehl, Volker, et al.. (1998). Die Therapie des Morbus Hodgkin. Der Internist. 39(9). 917–926. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xinyang Liao Breakdown of academic impact, for papers by Ioannis Vamvakaris Breakdown of academic impact, for papers by Corrina M. de Ridder Breakdown of academic impact, for papers by Sheng Cheng Breakdown of academic impact, for papers by Lei‐Ya Fang Breakdown of academic impact, for papers by Haojun Yang Breakdown of academic impact, for papers by Peter M. Gulleman Breakdown of academic impact, for papers by Julien Ancel Breakdown of academic impact, for papers by Jean‐Jacques Cassiman Breakdown of academic impact, for papers by Herbert Archer
Rankless by CCL
2026